Showing 8901-8910 of 9757 results for "".
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- Researchers ID Sensor Underlying Mechanical Itchhttps://practicaldermatology.com/news/researchers-id-sensor-underlying-mechanical-itch/2461248/Scientists at Scripps Research have identified a protein in sensory nerves that works as a key detector of the “mechanical” itch stimulus of crawling insects, wool fibers, or other irritating objects that touch the skin. The discovery, published June 22, 2022, in Nature
- Sciton Taps Bryant Wong as First Chief Financial Officerhttps://practicaldermatology.com/news/sciton-taps-bryant-wong-as-first-chief-financial-officer/2461246/Bryant Wong is Sciton’s first Chief Financial Officer, effective immediately. The announcement was made at Sciton's 25th Anniversary celebration. The year 2022 exemplifies Sciton's ongoing commitment to quality and improvement, with recognition such as 2022 Company of the
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effec
- 2022 Monkeypox Outbreak: Here’s What Dermatologists Need to Knowhttps://practicaldermatology.com/news/2022-monkeypox-outbreak-heres-what-dermatologists-need-to-know/2461210/As case counts of monkeypox cases increase in Europe and other parts of the globe including the US, dermatologists may have an important role to play in terms of making differential diagnoses. George Han, MD a dermatologist at Lenox Hill Hospital in New York City, spoke to Practical
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- Murad Joins Forces with Sesame to Offer Skin Care Consults with Dermatologists, Primary Care Doctorshttps://practicaldermatology.com/news/murad-joins-forces-with-sesame-to-offer-skin-care-consults-with-dermatologists-primary-care-doctors/2461194/Murad is partnering with Sesame to introduce skin consultations with board-certified dermatologists and primary care clinicians. <
- ISHRS 2022 Practice Consensus Results: Hair Restoration Trendshttps://practicaldermatology.com/news/ishrs-2022-practice-consensus-results-hair-restoration-trends/2461192/The International Society of Hair Restoration Surgery (ISHRS) released resutls of a new member survey that found 68 percent of members performed an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improvement, as ISHRS memb
- Study: Improved Survival Seen for DecisionDx-Melanoma Tested Patientshttps://practicaldermatology.com/news/study-improved-survival-seen-for-decisiondx-melanoma-tested-patients/2461168/Melanoma patients tested with DecisionDx-Melanoma plus traditional clinicopathologic factors showed improved survival compared to patients tested with only traditional clinicopathologic factors available to determine their treatment and follow-up plan, according to data presented the 18th Europea